New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days
Check below for free stories on DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
September 18, 2014
09:36 EDTVVUSActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL YHOO TWTR VVUS RAD PWE WFM TSLA PIR SHLD
09:32 EDTNFLXNetflix domestic estimates raised at ITG Research
ITG raised Netflix's domestic estimates given an acceleration in August. The firm's data indicates a faster than expected improvement in ASP and improved churn trends. The analyst raised its Q3 domestic streaming revenue of $881.3M from $877.3M, above guidance of $877M and consensus of $876.3M.
09:02 EDTMCKRite Aid sees current competitive enviornment to remain promotional in FY15
Subscribe for More Information
08:59 EDTVVUSOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTMRKNeogen's dairy genomic program to be marketed by Merck
Subscribe for More Information
06:12 EDTGDOTGreen Dot to acquire Santa Barbara Tax Products Group for $320M
Subscribe for More Information
06:08 EDTGDOTGreen Dot expects to launch 'major new program' to make positive 2014 impact
Subscribe for More Information
06:06 EDTGDOTGreen Dot cuts FY14 adjusted EBITDA to $122M-$126M from $128M-$132M
Subscribe for More Information
06:05 EDTGDOTGreen Dot cuts FY14 non-GAAP revenue to $610M-$620M from $640M-$650M
Subscribe for More Information
06:05 EDTVVUSVIVUS, Auxilium announce FDA approval of STENDRA sNDA
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has approved a supplemental new drug application, or sNDA, for STENDRA. STENDRA is now the only FDA-approved erectile dysfunction, or ED, medication indicated to be taken as early as approximately 15 minutes before sexual activity. STENDRA is a prescription medication in a class of drugs known as phosphodiesterase type 5, or PDE5, inhibitors approved for the treatment of ED in men 18 years or older. STENDRA is available in multiple dosage strengths and may be taken with or without food and moderate alcohol consumption. In clinical studies, when compared to placebo, STENDRA helped more men achieve an erection in as early as approximately 15 minutes that lasted long enough to successfully complete sexual intercourse.
06:04 EDTGDOTGreen Dot cuts FY14 non-GAAP EPS $1.25-$1.29 from $1.37-$1.41, consensus $1.42
Subscribe for More Information
06:00 EDTNFLXNetflix implied volatility of 26 at lower end of index mean range
Subscribe for More Information
September 17, 2014
09:33 EDTMRKMerck announced positive results from Phase 3 data for omarigliptin
Subscribe for More Information
08:31 EDTMRKMerck, Sun Pharma enter into licensing agreement for Tildrakizumab
Merck and Sun Pharmaceutical Industries, through their respective subsidiaries,announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80M. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.
September 16, 2014
16:00 EDTNFLXOptions Update; September 16, 2014
Subscribe for More Information
13:20 EDTNFLXNetflix signs two year commitment to Judd Apatow original comedy series
Subscribe for More Information
11:51 EDTNFLXNetflix breaks support, levels to watch
The stock was last at $451.51, putting price below the 50-day moving average at $453.67. That level is now resistance. On a technical basis the shares have swung from a sideways consolidation phase to bearish, with this break suggesting a pickup in downside momentum. Next support is at $445.85.
09:59 EDTGDOTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ACI Worldwide (ACIW) initiated with a Neutral at Sterne Agee... ADP (ADP) initiated with a Market Perform at Bernstein... ANSYS (ANSS) initiated with a Sector Perform at RBC Capital... Accenture (ACN) initiated with a Market Perform at Bernstein... Blackhawk (HAWK) initiated with a Neutral at Sterne Agee... Coca-Cola (KO) initiated with a Market Perform at Cowen... Cognizant (CTSH) initiated with an Outperform at Bernstein... Constellation Brands (STZ) initiated with a Market Perform at Cowen... Dr Pepper Snapple (DPS) initiated with a Market Perform at Cowen... GenCorp (GY) initiated with a Hold at KeyBanc... Global Payments (GPN) initiated with a Neutral at Piper Jaffray... GoPro (GPRO) initiated with a Buy at Cleveland Research... Green Dot (GDOT) initiated with a Neutral at Sterne Agee... Lionsgate (LGF) initiated with a Buy at ISI Group... MEDNAX (MD) initiated with a Neutral at SunTrust... MasterCard (MA) initiated with a Buy at Sterne Agee... Molson Coors (TAP) initiated with an Outperform at Cowen... Monster Beverage (MNST) initiated with a Market Perform at Cowen... NetSuite (N) initiated with an Outperform at RBC Capital... Oracle (ORCL) assumed with a Sector Perform at RBC Capital... PepsiCo (PEP) initiated with an Outperform at Cowen... SAP (SAP) initiated with a Sector Perform at RBC Capital... Teekay (TK) initiated with a Hold at Deutsche Bank... Tesla (TSLA) initiated with a Buy at ISI Group... Visa (V) initiated with a Buy at Sterne Agee... Western Union (WU) initiated with a Neutral at Sterne Agee... Workday (WDAY) initiated with an Outperform at RBC Capital... Yelp (YELP) initiated with a Neutral at RW Baird... Zillow (Z) initiated with an Overweight at Stephens... zulily (ZU) initiated with an Outperform at RW Baird.
09:36 EDTNFLXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX TSLA YHOO FB PBR MU AA TWTR WMT
08:18 EDTNFLXFCC to hold a roundtable
Subscribe for More Information
07:31 EDTMRKEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:25 EDTMRKMerck price target raised to $72 from $62 at SunTrust
After meeting with Merck's CEO and head of clinical development, SunTrust increased its price target on the company as the firm thinks that it is ideally positioned across five of the fastest growing therapeutic classes. The firm believes that the company's EPS growth rates from 2015-2020 will be three percentage points above Street estimates, while it has a first-mover advantage in oncology. It keeps a Buy rating on the shares.
05:57 EDTNFLXNetflix implied volatility of 26 at lower end of index mean range
Subscribe for More Information
September 15, 2014
16:32 EDTGDOTGreen Dot initiated with a Neutral at Sterne Agee
Target $17.
16:00 EDTNFLXOptions Update; September 15, 2014
iPath S&P 500 VIX Short-Term Futures up 73c to 29.34 Option volume leaders: AAPL TSLA NFLX BAC TWTR AMZN BP NFLX YHOO FB VLO according to Track Data.
15:49 EDTNFLXNetflix receives hostile reception in France, Telegraph says
Hostility from state-subsidized local media in France accompanied the launch of Netflix in the country today, says the Telegraph. The French are apprehensive that Netflix will erode the French "cultural exception," added the Telegraph. Reference Link
14:30 EDTNFLXNetflix volatility stays low end of historic range a shares pullback
Netflix September call option implied volatility is at 24, October is at 27, January is at 31; compared to its 26-week average of 37 according to Track Data, suggesting decreasing price movement.
13:30 EDTMRKMerck announces data from pivotal Phase 3 study for odanacatib
Merck announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Merck’s investigational once-weekly cathepsin K inhibitor. In the Long-Term Odanacatib Fracture Trial, odanacatib met its primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with placebo. The rates of adverse events overall in LOFT were generally balanced between patients taking odanacatib and placebo. Adjudicated events of morphea-like skin lesions and atypical femoral fractures occurred more often in the odanacatib group than in the placebo group. Adjudicated major adverse cardiovascular events were generally balanced overall between the treatment groups. There were numerically more adjudicated stroke events with odanacatib than with placebo.
09:35 EDTNFLXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA RSH YHOO GILD TWTR AVNR NFLX BAC C
07:55 EDTALKSAlkermes shares attractive ahead of Q1 catalysts, says Leerink
Leerink says its recent meeting with Alkermes management confirmed its conviction that the company is executing on its growth strategy. Leerink believes clinical trials for ALKS 8700 in multiple sclerosis, ALKS 7106 in abuse deterrent opiate analgesic and the Phase II trial for ALKS 3831 in schizophrenia are all billion dollar market opportunities that are not reflected in the current stock price. The firm finds the stock attractively valued ahead of clinical data readouts that start in early Q1 of 2015. It reiterates an Outperform rating on Alkermes with a $66 price target.
06:14 EDTNFLXNetflix launches in France
Netflix announced in a Tweet that it has launched in France. The service is expected to go live in five other countries later this week. Reference Link
September 14, 2014
14:33 EDTNFLXNetflix to face competition in France from Numericable Group , WSJ says
In a move to counter the planned arrival of Netflix in France, French cable company Numericable Group announced it will launch a service to give subscribers free access to hundreds of TV series, says the Wall Street Journal. Reference Link
September 12, 2014
16:00 EDTNFLXOptions Update; September 12, 2014
Subscribe for More Information
12:48 EDTNFLXBarclays upgrades Netflix citing recent underperformance, new markets
Subscribe for More Information
10:00 EDTNFLXOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Cedar Realty Trust (CDR) upgraded to Buy from Hold at KeyBanc... E.ON AG (EONGY) upgraded to Overweight from Neutral at JPMorgan... Genuine Parts (GPC) upgraded to Buy from Hold at BB&T... Inland Real Estate (IRC) upgraded at KeyBanc... Littelfuse (LFUS) upgraded to Outperform from Perform at Oppenheimer... Netflix (NFLX) upgraded to Equal Weight from Underweight at Barclays... Noranda Aluminum (NOR) upgraded to Buy from Neutral at Goldman... OCI Partners (OCIP) upgraded to Buy from Neutral at Citigroup... Ramco-Gershenson (RPT) upgraded at KeyBanc... Sprint (S) upgraded to Outperform from Market Perform at Cowen... T-Mobile (TMUS) upgraded to Buy from Hold at Argus... The Advisory Board (ABCO) upgraded to Outperform at Wells Fargo.
05:31 EDTNFLXNetflix upgraded to Equal Weight from Underweight at Barclays
Barclays upgraded its rating on Netflix (NFLX) shares to Equal Weight from Underweight saying its international estimates are likely achievable and it no longer sees the stock underperforming peers. Barclays raised its price target for Netflix to $480 from $420. The stock closed yesterday down $2.83 to $481.56.
September 11, 2014
16:00 EDTNFLXOptions Update; September 11, 2014
Subscribe for More Information
12:42 EDTVVUSOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
12:05 EDTTSNUSDA lowers forecasts for 2014, 2015 meat production
Subscribe for More Information
10:59 EDTVVUSArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
09:37 EDTNFLXActive equity options trading on open
Subscribe for More Information
08:01 EDTVVUSOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
September 10, 2014
16:00 EDTMRK, NFLXOptions Update; September 10, 2014
Subscribe for More Information
10:26 EDTNFLXDiscovery CEO says likes doing deals with Netflix, Amazon
CEO David Zaslav says Comcast (CMCSA)/Time Warner Cable (TWC) deal "presents some serious issues," is talking to FCC about deal. Says will be opportunistic with international acquisitions, but "We don't feel like we need to acquire anything at this point." Says has more subscribers than ESPN with Europsport. Comments made at the Goldman Sachs Communacopia Conference.
10:00 EDTNFLXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:05 EDTTSNTyson Foods reinstated with a Buy at Goldman
Target $46.
08:34 EDTCTRPCtrip.com confirms removal of hotel listings from Qunar, Marbridge Daily says
Subscribe for More Information
06:26 EDTNFLXNetflix initiated with a Neutral at SunTrust
Subscribe for More Information
06:04 EDTNFLXNetflix initiated with a Buy at Canaccord
Target $550.
September 9, 2014
12:55 EDTNFLXNetflix advances after analyst ups target to $600
Subscribe for More Information
12:46 EDTVVUSNovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
12:28 EDTCTRPCtrip.com removed products from Qunar site, GeoInvesting says
GeoInvesting tweeted that after visiting Qunar's (QUNR) website it confirmed Ctrip.com (CTRP) has removed its hotel products from Qunar's website. Shares of Qunar are down 3% to $30.80 in midday trading.
09:36 EDTNFLXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL KNDI NFLX YHOO TWTR TSLA C BAC FB MCD
08:22 EDTNFLXNetflix price target raised to $600 from $530 at RBC Capital
Subscribe for More Information
07:31 EDTNFLXNetflix enters online U.S. net neutrality strike, Reuters says
Subscribe for More Information
06:51 EDTALKSAlkermes management to meet with Leerink
Subscribe for More Information
September 8, 2014
16:00 EDTMRK, NFLXOptions Update; September 8, 2014
Subscribe for More Information
09:40 EDTNFLXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TWTR TSLA YHOO BAC FB MSFT NFLX GILD MCD
09:39 EDTLTMHG Vora reports 5.1% passive stake in Life Time Fitness
Subscribe for More Information
07:42 EDTNFLXNetflix expands in Europe amid scrutiny, skepticism, WSJ says
Subscribe for More Information
07:26 EDTMCKMorgan Stanley to hold a conference
Subscribe for More Information
September 5, 2014
16:45 EDTMRKMarket ends week little changed after mixed economic data
Subscribe for More Information
12:57 EDTLTMOn The Fly: Midday Wrap
Subscribe for More Information
11:17 EDTMRKBristol-Myers files patent infringement suit against Merck
Subscribe for More Information
09:02 EDTLTMLife Time Fitness holder Marcato supports REIT, sees $70 per share possible
Subscribe for More Information
08:39 EDTMRKMerck Keytruda sales to reach $5B in 2018, says BMO Capital
Subscribe for More Information
September 4, 2014
16:00 EDTNFLXOptions Update; September 4, 2014
Subscribe for More Information
15:16 EDTMRKMerck receives accelerated approval of Keytruda
Subscribe for More Information
09:26 EDTTSNTyson Foods backs FY14 EPS ex-items view of at least $2.78 per share
Consensus $2.81. Tyson CFO Dennis Leatherby stated at the Barclays Back-to-School Consumer Conference that he expects the addition of Hillshire to be accretive to earnings in fiscal 2015 and substantially accretive thereafter, adding that he expects at least 10% EPS growth in FY15.
09:24 EDTTSNTyson Foods CEO says moving forward quickly with Hillshire integration
Tyson President and CEO Donnie Smith told investors at the annual Barclays Back-to-School Consumer Conference that the process for combining the company with Hillshire is well underway, stating, "We're moving forward quickly with the integration and finding synergies, and we feel good about our ability to capture $225M in synergies in the first year and $500M by year three." Smith added, "The more we get into it, the better we feel," according to presentation recap provided by the company.
09:02 EDTMRKMerck's relebactam granted QIDP, fast track designations by FDA
Merck announced that the U.S. Food and Drug Administration has designated relebactam -- previously known as MK-7655 -- the company’s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product with designated Fast Track status. The QIDP and Fast Track designations apply to intravenous use of relebactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Relebactam is an investigational, class A and C, beta-lactamase inhibitor that is being evaluated in combination with imipenem/cilastatin in ongoing Phase 2 clinical trials for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. In preclinical studies, relebactam administered in combination with imipenem/cilastatin demonstrated antibacterial activity against a broad range of Gram-negative and beta-lactam-resistant pathogens. Merck plans to initiate Phase 3 studies with relebactam in combination with imipenem/cilastatin in 2015.
07:21 EDTMRKMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use